UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 
−Removed: During the three months ended June 30, 2022, the Company issued warrants to purchase 50,000 shares of common stock with an exercise price of $1.49 per share to two entities providing clinical trial advisory services, which warrants will vest annually over four years while services are being performed. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.
+Added: During the three months ended September 30, 2022, the Company entered into a portfolio advisory agreement with a related party entity, associated with Dr.
+Added: Waldemar Priebe, and in connection with the agreement, the Company granted equity-classified warrants to purchase 250,000 shares of common stock with a ten-year term and an exercise price of $1.24.
+Added: The September 2022 warrants vest as follows:
+Added: (a) 50% vests upon execution of the agreement, provided the advisor does not terminate the agreement prior to the first anniversary of the agreement;
+Added: and (b) 50% vests 60 days after the end of the one-year term, subject to the Company's Board of Directors determining that the services provided have been adequately performed. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.
DEFAULTS UPON SENIOR SECURITIES
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.